目的 探討丹梔逍遙丸聯(lián)合瑞舒伐他汀鈣片治療非酒精性脂肪肝的臨床療效。方法 選取2014年11月-2016年12月襄陽市中心醫(yī)院收治的非酒精性脂肪性肝病患者125例為研究對象，所有患者根據(jù)隨機原則分為對照組（65例）和治療組（60例）。對照組口服瑞舒伐他汀鈣片，起始劑量10 mg/次，1次/d，治療4周后根據(jù)血脂水平調(diào)整劑量，單日最大劑量不超過20 mg。治療組在對照組的基礎(chǔ)上口服丹梔逍遙丸，6 g/次，2次/d。28 d為1個療程，兩組患者治療3個療程后評價療效。觀察兩組的臨床療效，比較兩組的肝功能指標(biāo)、血脂水平和肝脾電子計算機斷層掃描（CT）比值。結(jié)果 治療后，對照組和治療組的總有效率分別為84.62%、93.33%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)氨酶（AST）、谷氨酰轉(zhuǎn)肽酶（GGT）水平均明顯下降，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些肝功能指標(biāo)明顯低于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組總膽固醇（TC）、三酰甘油（TG）水平明顯下降，高密度脂蛋白膽固醇（HDL-C）水平明顯升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些血脂指標(biāo)水平明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組肝脾CT比值明顯升高，同組治療前后比較差異具有統(tǒng)計學(xué)意義（P<0.05）；且治療組肝脾CT比值明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 丹梔逍遙丸聯(lián)合瑞舒伐他汀鈣片能夠協(xié)同治療非酒精性脂肪性肝病，改善肝功能指標(biāo)和血脂水平，減輕脂肪肝嚴(yán)重程度，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Danzhi Xiaoyao Pills combined with Rosuvastatin Calcium Tablets in treatment of nonalcoholic fatty liver. Methods Patients (125 cases) with nonalcoholic fatty liver in Xiangyang Central Hospital from November 2014 to December 2016 were randomly divided into the control group (65 cases) and the treatment group (60 cases). Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily, after treatment for 4 weeks, the dose was adjusted according to the blood lipid level. The maximum dose was not more than 20 mg/d. Patients in the treatment group were po administered with Danzhi Xiaoyao Pills on the basis of the control group, 6 g/time, twice daily. One course of treatment was 28 d, and patients in two groups were treated for 3 courses. After treatment, the clinical efficacies were evaluated, and liver function indexes, blood lipid levels, and CT ratio of liver and spleen in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 84.62% and 93.33%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of ALT, AST, and GGT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of TC and TG in two groups were significantly decreased, but the levels of HDL-C in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the CT ratio of liver and spleen in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the CT ratio of liver and spleen in the treatment group was significantly higher than that in the control group, with significant difference between two groups (P < 0.05). Conclusion Danzhi Xiaoyao Pills combined with Rosuvastatin Calcium Tablets has clinical curative effect in treatment of nonalcoholic fatty liver, can improve liver function and blood lipid, reduce the severity of fatty liver, which has a certain clinical application value.